<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Novita Sari</style></author><author><style face="normal" font="default" size="100%">Bambang Pujo Semedi</style></author><author><style face="normal" font="default" size="100%">Prananda Surya Airlangga</style></author><author><style face="normal" font="default" size="100%">Kohar Hari Santoso</style></author><author><style face="normal" font="default" size="100%">Maulydia</style></author><author><style face="normal" font="default" size="100%">Budi Utomo</style></author><author><style face="normal" font="default" size="100%">Christrijogo Sumartono</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Can Ventilator Settings Influence Lung Damage Biomarkers KL-6 and CRP during One Lung Ventilation?</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">CRP</style></keyword><keyword><style  face="normal" font="default" size="100%">KL-6</style></keyword><keyword><style  face="normal" font="default" size="100%">One lung ventilation</style></keyword><keyword><style  face="normal" font="default" size="100%">Thoracotomy</style></keyword><keyword><style  face="normal" font="default" size="100%">Ventilator</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">April 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">455-459</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Volume-controlled (VCV) or pressure-controlled ventilation (PCV) modes are most often used during OLV. This is a prospective observational analytical study of patients undergoing thoracic surgery with OLV. &lt;strong&gt;Method:&lt;/strong&gt; 40 patients underwent thoracic surgery using one lung ventilation (OLV) from December 2023 to February 2024. All patients received lung protective ventilation (PLV) with a tidal volume of 6 ml/ kgPBW during OLV with PEEP 5-7 cmH2O and were divided into two groups: one with a ventilator in volume-controlled mode (VCV) and the other with pressure-controlled mode (PCV). KL-6, CRP, and p/f ratio were measured before OLV, 2 hours after OLV, and 24 hours after the operation was completed. Respiratory variables during OLV were recorded. &lt;strong&gt;Results:&lt;/strong&gt; KL-6 and CRP levels in PCV and VCV groups were significantly different. There were significant differences in the values of Ppeak (p &amp;lt;0.001), PEEP (p = 0.008), Cstat (p = 0.004) and driving pressure (p &amp;lt;0.001) in both groups. The correlation between changes in KL-6 and CRP levels and the P/F ratio were very weak and insignificant. Cytokines play an important role in the inflammatory response in the lungs. Several determining factors of blood flow are gravity, lung disease, surgery, and hypoxic pulmonary vasoconstriction. Duration of OLV may affect the pulmonary inflammatory response and is correlated with the duration of OLV.&lt;strong&gt; Conclusion: &lt;/strong&gt;There is no association found between KL-6 and CRP in PCV and VCV mode during thoracotomy with OLV.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">455</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Novita Sari&lt;sup&gt;1&lt;/sup&gt;, Bambang Pujo Semedi&lt;sup&gt;2*&lt;/sup&gt;, Prananda Surya Airlangga&lt;sup&gt;2&lt;/sup&gt;, Kohar Hari Santoso&lt;sup&gt;2&lt;/sup&gt;, Maulydia&lt;sup&gt;2&lt;/sup&gt;, Budi Utomo&lt;sup&gt;3&lt;/sup&gt;, Christrijogo Sumartono&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Study Program of Anesthesiology and Intensive Care, Faculty of Medicine, University of Airlangga – Dr Soetomo General Hospital, Surabaya, Indonesia&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Anesthesiology and Intensive Care, Faculty of Medicine, University of Airlangga – Dr Soetomo General Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Public Health and Preventive Medicine, Faculty of Medicine, University of Airlangga – Dr Soetomo General Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wibowo Artho Sutrisno</style></author><author><style face="normal" font="default" size="100%">Prananda Surya Airlangga</style></author><author><style face="normal" font="default" size="100%">Citrawati Dyah Kencono Wungu</style></author><author><style face="normal" font="default" size="100%">Prihatma Kriswidyatomo</style></author><author><style face="normal" font="default" size="100%">Hamzah</style></author><author><style face="normal" font="default" size="100%">Bambang Pujo Semedi</style></author><author><style face="normal" font="default" size="100%">Mahmudah</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Role of Neuron Specific Enolase, S100B, Glial Fibrillary Acidic Protein, and Myelin Basic Protein as Prognostic and Survival Values in Traumatic Brain Injury: Systematic Review and Meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Glial Fibriallary Acidic Protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Myelin Basic Protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Neuron Specific Enolase</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognostic Value</style></keyword><keyword><style  face="normal" font="default" size="100%">S100B</style></keyword><keyword><style  face="normal" font="default" size="100%">Survival</style></keyword><keyword><style  face="normal" font="default" size="100%">Traumatic Brain Injury</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">April 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">478-484</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;The high number of accidents and traumatic brain injuries, especially in the productive age group, causes a lot of morbidity and mortality. A fast and accurate examination method is needed for the diagnosis and treatment of traumatic brain injury. Nerve damage biomarkers such as Neuron Specific Enolase, S100B, Glial Fibrillary Acidic Protein, and Myelin Basic Protein, have been used globally both for research and daily use to determine the severity of traumatic brain injury. &lt;strong&gt;Methods:&lt;/strong&gt; Searches and journal searches were carried out from Science Direct, Scopus, Springer Link, and PubMed, with the keywords &quot;Neuron Specific Enolase&quot;, &quot;S100B&quot;, &quot;Glial Fibrillary Acidic Protein&quot;, &quot;Myelin Basic Protein&quot;, and &quot;Traumatic Brain Injury ”. Screening was carried out using PRISMA 2021 to look for studies that met the criteria and were of sufficient study quality according to the Newcastle-Ottawa Scale. &lt;strong&gt;Results: &lt;/strong&gt;Twenty-three studies were collected and further grouped based on outcomes, both prognostic and survival outcomes. Neuron Specific Enolase, S100B, and Glial Fibrillary Acidic Protein values were higher in poor outcomes (all p values &amp;lt; 0.001) and poor survival (all p values &amp;lt; 0.001) in traumatic brain injury. Myelin Basic Protein was not significant in poor outcome (p = 0.35), but was higher in poor survival (p &amp;lt; 0.001) in traumatic brain injury. &lt;strong&gt;Conclusion:&lt;/strong&gt; Neuron Specific Enolase, S100B, and Glial Fibrillary Acidic Protein, can be used as markers for prognostic and survival value in traumatic brain injury. Myelin Basic Protein can be used as a marker for survival value in traumatic brain injury.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Review Article</style></work-type><section><style face="normal" font="default" size="100%">478</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Wibowo Artho Sutrisno&lt;sup&gt;1&lt;/sup&gt;, Prananda Surya Airlangga&lt;sup&gt;1*&lt;/sup&gt;, Citrawati Dyah Kencono Wungu&lt;sup&gt;2&lt;/sup&gt;, Prihatma Kriswidyatomo&lt;sup&gt;1&lt;/sup&gt;, Hamzah1, Bambang Pujo Semedi&lt;sup&gt;1&lt;/sup&gt;, Mahmudah&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Anesthesiology and Reanimation, Faculty of Medicine, Airlangga University - Dr Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Physiology and Medical Biochemistry, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA. 3Department of Community Health, Faculty of Community Health, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Etty Hary Kusumastuti</style></author><author><style face="normal" font="default" size="100%">Priangga Adi Wiratama</style></author><author><style face="normal" font="default" size="100%">Grace Ariani</style></author><author><style face="normal" font="default" size="100%">Stephanie Natasha Djuanda</style></author><author><style face="normal" font="default" size="100%">Alphania Rahniayu</style></author><author><style face="normal" font="default" size="100%">Nila Kurniasari</style></author><author><style face="normal" font="default" size="100%">Dyah Fauziah</style></author><author><style face="normal" font="default" size="100%">Anny Setijo Rahaju</style></author><author><style face="normal" font="default" size="100%">Isnin Anang Marhana</style></author><author><style face="normal" font="default" size="100%">Alfian Nur Rosyid</style></author><author><style face="normal" font="default" size="100%">Dwi Wahyu</style></author><author><style face="normal" font="default" size="100%">Gilang Muhammad Setyo Nugroho</style></author><author><style face="normal" font="default" size="100%">Adhitri Anggoro</style></author><author><style face="normal" font="default" size="100%">I Komang Rusgi Yandi</style></author><author><style face="normal" font="default" size="100%">Bambang Pujo Semedi</style></author><author><style face="normal" font="default" size="100%">Jilientasia Godrace Lilihata</style></author><author><style face="normal" font="default" size="100%">Ummi Maimunah</style></author><author><style face="normal" font="default" size="100%">Supriadi</style></author><author><style face="normal" font="default" size="100%">Achmad Lefi</style></author><author><style face="normal" font="default" size="100%">Lalu Galih Pratama Rinjani</style></author><author><style face="normal" font="default" size="100%">Edi Suyanto</style></author><author><style face="normal" font="default" size="100%">Ricardo Ardian Nugraha</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Differences in interleukin-6 and interleukin-17 expression in covid-19 post-mortem lung tissue biopsy compared with noncovid- 19</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Biopsy</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">IL-17</style></keyword><keyword><style  face="normal" font="default" size="100%">IL-6</style></keyword><keyword><style  face="normal" font="default" size="100%">Post mortem lung tissue.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">January 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">887-892</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; COVID-19 has spread rapidly around the world. It is necessary to study lung tissue of postmortem COVID19 patients to determine the molecular alteration particularly the role of IL-6 and IL-17 in causing fatality. &lt;strong&gt;Objective:&lt;/strong&gt; This study aims to determine the differences in the expressions of IL-6 and IL-17 in lung tissue of post-mortem COVID-19 patients compared to non-COVID-19 patients. This study also aimed to analyze the correlation between the expressions of IL-6 and IL-17 in lung tissue of post-mortem COVID-19 patients. Methods: This research is an observational analytic study with crosssectional approach. The samples were 15 paraffin blocks of post-mortem lung tissue biopsy of COVID-19 patients, and 15 paraffin blocks of inflammatory lung tissue biopsy or surgery of non-COVID-19 patients. IL-6 and IL-17 expressions were evaluated by immunohistochemical procedure. &lt;strong&gt;Result: &lt;/strong&gt;There was a significant difference in the expression of IL-6 in the COVID-19 group and the non-COVID-19 group with a p-value = 0.001 (p &amp;lt; 0.05). There was a significant difference in the expression of IL-17 in the COVID-19 group and the non-COVID-19 group with p-value = 0.001 (p &amp;lt; 0.05). There was a significant correlation between the expressions of IL-6 and IL-17 in the COVID-19 group, with the Spearman coefficient value (rs) of 0.548 with p = 0.034 (p &amp;lt; 0.05).&lt;strong&gt; Conclusion:&lt;/strong&gt; There are differences in the expression of IL-6 and IL-17 between COVID-19 and non-COVID-19 lung tissue. There is a significant correlation between the expressions of IL-6 and IL-17 in post-mortem lung tissue of COVID-19 patients.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">887</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Etty Hary Kusumastuti&lt;sup&gt;1,*&lt;/sup&gt;, Priangga Adi Wiratama&lt;sup&gt;1&lt;/sup&gt;, Grace Ariani&lt;sup&gt;1&lt;/sup&gt;, Stephanie Natasha Djuanda&lt;sup&gt;1&lt;/sup&gt;, Alphania Rahniayu&lt;sup&gt;1&lt;/sup&gt;, Nila Kurniasari&lt;sup&gt;1&lt;/sup&gt;, Dyah Fauziah1, Anny Setijo Rahaju&lt;sup&gt;1&lt;/sup&gt;, Isnin Anang Marhana&lt;sup&gt;2&lt;/sup&gt;, Alfian Nur Rosyid&lt;sup&gt;2&lt;/sup&gt;, Dwi Wahyu&lt;sup&gt;2&lt;/sup&gt;, Gilang Muhammad Setyo Nugroho&lt;sup&gt;2&lt;/sup&gt;, Adhitri Anggoro&lt;sup&gt;2&lt;/sup&gt;, I Komang Rusgi Yandi&lt;sup&gt;2&lt;/sup&gt; Bambang Pujo Semedi&lt;sup&gt;3&lt;/sup&gt;, Jilientasia Godrace Lilihata&lt;sup&gt;3&lt;/sup&gt;, Ummi Maimunah&lt;sup&gt;4&lt;/sup&gt;, Supriadi&lt;sup&gt;4&lt;/sup&gt;, Achmad Lefi&lt;sup&gt;5&lt;/sup&gt;, Lalu Galih Pratama Rinjani&lt;sup&gt;5&lt;/sup&gt;, Edi Suyanto&lt;sup&gt;6&lt;/sup&gt;, Ricardo Ardian Nugraha&lt;sup&gt;6&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Anesthesiology and Reanimation, Faculty of Medicine, Universitas Airlangga University – Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;Department of Forensics and Medicolegal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>